3B Blackbio Dx Limited Q4 FY26 results deck summary

Results deck of 29 May 2026, summarised by AI from the filing.

FY 2025-26 consolidated revenue ₹14,191.81 cr with PAT ₹5,992.98 cr; MDx guided to grow 15%–20% in FY 2026–27.

Key takeaways

1. FY26 results Consolidated revenue from operations ₹14,191.81 cr (FY 2024-25: ₹9,646.86 cr), PAT ₹5,992.98 cr (FY 2024-25: ₹4,769.17 cr).
2. Guidance Management hopes to grow MDx 15%–20% overall in FY 2026–27, taking both domestic and export sales.
3. Change Coris BioConcept SRL, Belgium was acquired on 29th August and consolidated from the date of acquisition, adding CORIS sales of ₹3,591.19 cr in FY 2025-26.
4. Driver TRUPCR Europe Limited sales grew 36% in FY 2025-26 with a 40.3% CAGR over four years, driven by Made in UK portfolio acceptance across Europe.

Original filing on BSE

3B Blackbio Dx Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (13 Aug 2026)
• Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
• Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
• Q2 FY26: Results deck (13 Nov 2025)
• Q1 FY26: Earnings call (19 Aug 2025)
• Q4 FY25: Results deck (28 May 2025)
• Other events: Strategy deck (14 Aug 2025)